Related Experiment Video

Updated: Jun 16, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis

Betti Giusti1, Anna Maria Gori, Rossella Marcucci

  • 1University of Florence and SOD Atherothrombotic Diseases, Department of Medical and Surgical Critical Care, AOU Careggi, Viale Morgagni 85, 50134 Florence, Italy. betti.giusti@unifi.it

Expert Opinion on Drug Metabolism & Toxicology
|February 19, 2010
PubMed

Insights

The CYP2C19*2 gene variant reduces clopidogrel effectiveness, increasing cardiovascular risks in high-risk patients. Personalized treatment strategies are needed to manage these risks effectively.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacogenomics
  • Clinical Thrombosis

Background:

  • Dual antiplatelet therapy (clopidogrel and aspirin) is crucial for preventing ischemic events post-PCI and in acute coronary syndromes.
  • Residual platelet reactivity despite therapy is linked to adverse cardiovascular events, including stent thrombosis.
  • Clopidogrel metabolism by CYP isoenzymes, particularly CYP2C19, is essential for its antiplatelet effect.

Purpose of the Study:

  • To review studies linking CYP2C19*2 polymorphism to adverse outcomes in patients on clopidogrel.
  • To highlight the clinical significance of genetic variations in antiplatelet therapy response.

Main Methods:

  • Systematic review of principal studies.
  • Analysis of the relationship between CYP2C19*2 genotype and clinical outcomes.
  • Evaluation of studies on residual platelet reactivity and clopidogrel efficacy.

Main Results:

  • CYP2C19*2 polymorphism is associated with reduced clopidogrel metabolization.
  • This reduced metabolism leads to diminished antiplatelet effect and increased risk of adverse cardiovascular events.
  • High residual platelet reactivity in patients with CYP2C19*2 polymorphism correlates with poorer outcomes.

Conclusions:

  • CYP2C19*2 genotype significantly impacts clopidogrel efficacy and patient outcomes.
  • A comprehensive risk assessment score, including genetic factors, is needed for personalized antiplatelet therapy.
  • Further prospective studies are required to validate individualized therapeutic strategies for high-risk vascular patients.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...